Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1.

Zhang J, Li Y, Guo L, Cao R, Zhao P, Jiang W, Ma Q, Yi H, Li Z, Jiang J, Wu J, Wang Y, Si S.

Cancer Biol Ther. 2009 Dec;8(24):2374-83. Epub 2009 Dec 27.

PMID:
19855194
2.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M.

Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.

3.

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP.

Cancer Cell. 2005 Mar;7(3):275-86. Erratum in: Cancer Cell. 2005 May;7(5):497. Boomi Nathan, R [corrected to Boominathan, R].

4.

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.

Curr Biol. 2007 Feb 20;17(4):316-22. Epub 2007 Feb 8.

5.

Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.

Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.

Cancer Res. 2009 Sep 1;69(17):6969-77. doi: 10.1158/0008-5472.CAN-09-0945. Epub 2009 Aug 18.

6.

Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.

Lan R, Lin G, Yin F, Xu J, Zhang X, Wang J, Wang Y, Gong J, Ding YH, Yang Z, Lu F, Zhang H.

Lab Invest. 2012 Oct;92(10):1503-14. doi: 10.1038/labinvest.2012.114. Epub 2012 Aug 13.

7.

The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM.

Curr Biol. 2007 Feb 20;17(4):304-15. Epub 2007 Feb 8.

8.

The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.

Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X.

Acta Pharmacol Sin. 2009 Oct;30(10):1443-53. doi: 10.1038/aps.2009.141.

9.

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.

Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M, Strebhardt K.

Oncogene. 2002 May 9;21(20):3162-71.

10.

Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.

Ismail IA, Kang KS, Lee HA, Kim JW, Sohn YK.

Eur J Pharmacol. 2007 Dec 1;575(1-3):12-20. Epub 2007 Jul 28.

PMID:
17706963
11.

Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos.

Jeong K, Jeong JY, Lee HO, Choi E, Lee H.

Dev Biol. 2010 Sep 1;345(1):34-48. doi: 10.1016/j.ydbio.2010.06.004. Epub 2010 Jun 8.

12.

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.

Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.

PMID:
21399492
14.

Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.

Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):253-60. doi: 10.1016/j.ijrobp.2009.11.027.

PMID:
20394857
15.

Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1.

Neef R, Gruneberg U, Kopajtich R, Li X, Nigg EA, Sillje H, Barr FA.

Nat Cell Biol. 2007 Apr;9(4):436-44. Epub 2007 Mar 11.

PMID:
17351640
16.

A series of beta-carboline derivatives inhibit the kinase activity of PLKs.

Han X, Zhang J, Guo L, Cao R, Li Y, Li N, Ma Q, Wu J, Wang Y, Si S.

PLoS One. 2012;7(10):e46546. doi: 10.1371/journal.pone.0046546. Epub 2012 Oct 3.

17.

Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells.

Schmidt M, Hofmann HP, Sanders K, Sczakiel G, Beckers TL, Gekeler V.

Mol Cancer Ther. 2006 Apr;5(4):809-17.

18.

DH334, a beta-carboline anti-cancer drug, inhibits the CDK activity of budding yeast.

Li Y, Liang F, Jiang W, Yu F, Cao R, Ma Q, Dai X, Jiang J, Wang Y, Si S.

Cancer Biol Ther. 2007 Aug;6(8):1193-9. Epub 2007 May 4.

PMID:
17622795
19.

Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death.

O'Donovan DS, MacFhearraigh S, Whitfield J, Swigart LB, Evan GI, Mc Gee MM.

Cell Death Dis. 2013 Jan 24;4:e468. doi: 10.1038/cddis.2012.208.

20.

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.

Chem Biol. 2008 May;15(5):459-66. doi: 10.1016/j.chembiol.2008.03.013.

Supplemental Content

Support Center